Veterinary Parasiticides Market Report 2025

This Veterinary Parasiticides market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The veterinary parasiticides market size has grown strongly in recent years. It will grow from $14.93 billion in 2024 to $15.85 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to animal health awareness, livestock production, companion animal ownership, zoonotic diseases.

The veterinary parasiticides market size is expected to see strong growth in the next few years. It will grow to $20.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to global food security, emerging zoonotic threats, companion animal care, environmental changes. Major trends in the forecast period include zoonotic disease concerns, flea and tick control innovation, parasiticide safety and environmental concerns, innovative delivery methods.

Zoonotic pathogens, which are increasingly affecting animals, are a leading cause of foodborne diseases worldwide. Zoonotic diseases, caused by bacteria, viruses, and parasites - such as Salmonella and Campylobacter - can be transmitted directly or indirectly between animals and humans. These diseases can pass through the food chain to humans, creating a significant public health threat and underscoring the urgent need to prevent such diseases in animals. For example, in December 2022, the European Food Safety Authority (EFSA), an Italy-based agency that provides independent scientific advice on food-related risks, reported that in 2021, Campylobacteriosis was the most commonly reported zoonotic disease, with 127,840 cases. Chicken and turkey meat were identified as the primary sources. Salmonellosis was the second most frequently reported zoonotic disease, affecting 60,050 individuals. This rising need to prevent infections in animals is driving the growth of the veterinary parasiticides market.

The increasing global adoption of pets is expected to drive the growth of the veterinary parasiticides market in the future. Pet adoption involves providing a permanent and caring home to a domesticated animal, often from sources like animal shelters, rescue organizations, or previous owners. Pet owners who adopt animals tend to be more responsible and health-conscious, leading to a higher demand for parasiticides to safeguard their pets from common parasites and maintain their overall well-being. Furthermore, shelter and rescue organizations frequently offer initial parasite prevention, further encouraging the use of these products. For example, in July 2022, according to the People's Dispensary for Sick Animals (PDSA), a veterinary charity based in the United Kingdom, there were approximately 10.2 million pet dogs, 11.1 million pet cats, and 1 million pet rabbits in the UK in 2022. Additionally, it was reported that 52% of adults in the UK were pet owners during the same year. Consequently, the increasing adoption of pets is a driving force behind the growth of the veterinary parasiticides market.

Chewable tablets have emerged as an effective method to prevent animals from being affected by ticks, worms, fleas, and other parasites. The administration of treatments through these chewable tablets is more convenient and user-friendly. These tablets are typically available in either beef-flavored or soft chew forms. For example, IVERHART MAX chewable tablets are designed to protect dogs from the four most common types of worms: heartworms (transmitted through the bite of an infected mosquito), roundworms, hookworms (affecting the intestines), and tapeworms (contracted by ingesting an infected flea). Such technological advancements are playing a significant role in propelling the veterinary parasiticides industry forward.

Prominent companies within the veterinary parasiticides market are actively engaged in the development of new medications designed to protect animals from parasites. Parasite protection encompasses the various measures, strategies, and products used to shield animals, whether they are pets or livestock, from infestations or infections by parasites like fleas, ticks, worms, and external pests. For instance, in April 2022, Vetoquinol, a pharmaceutical company based in France, introduced Felpreva, a novel feline spot-on parasiticide that represents a significant advancement in the field of companion animal parasitology. Felpreva offers three months of comprehensive protection against both endoparasites (internal) and ectoparasites (external) for cats. It is specifically designed to combat common feline parasites, including fleas, ticks, roundworms, tapeworms, and ear mites, all within a single, convenient dosage. This product is licensed for the treatment of cats with existing or potential mixed parasitic infestations or infections.

Major companies operating in the veterinary parasiticides market include Bayer AG, Zoetis Inc., Boehringer Ingelheim, Merck & Co. Inc., Eli Lilly and Company, virology and bacteriology, Ceva Animal Health, Merial Inc., Perrigo Company, Vetoquinol India Animal Health Pvt Ltd., Intas Pharmaceuticals Ltd., Perrigo Company, Eli Lilly and Company, Dechra Pharmaceuticals PLC, Lillidale Ltd., Phibro Animal Health Corporation, Bovian Health Care Pvt. Ltd., Sanofi SA, Novartis AG, Oceanic Pharmachem, IDEXX Laboratories Inc., Covetrus Inc., Norbrook Laboratories Limited, Bimeda Holdings PLC, PetIQ Inc., Heska Corporation, Neogen Corporation, Kyoritsu Seiyaku Corporation, Nexvet Biopharma PLC, Kepro Technologies Private Limited, ECO Animal Health Group PLC, Bioniche Animal Health Canada Inc., Bioiberica S.A., Laboratorios Hipra S.A., Norbrook Laboratories Limited.

Veterinary parasiticides are a class of animal medications used to combat parasites and improve the health of pets, livestock, and other animals. These medications work by inhibiting the activity of acetylcholinesterase, thus treating diseases caused by various parasites, such as helminths, amoeba, ectoparasites, parasitic fungi, protozoa, and others.

The primary types of veterinary parasiticides include endoparasiticides, ectoparasiticides, and endectocides. Endectocides are medications administered directly to hosts to target both endoparasites and ectoparasites, with a primary focus on blood-feeding arthropods. These parasiticides are available in various product forms, including oral liquids, tablets, injectables, sprays, and other formulations designed for farm animals and companion animals. They are commonly used by research and development facilities, farms, and veterinary clinics.

The veterinary parasiticides research report is one of a series of new reports that provides veterinary parasiticides statistics, including veterinary parasiticides industry global market size, regional shares, competitors with veterinary parasiticides share, detailed veterinary parasiticides segments, market trends and opportunities, and any further data you may need to thrive in the veterinary parasiticides industry. This veterinary parasiticides research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the veterinary parasiticides market in 2024. Asia-Pacific was the second-largest region in the veterinary parasiticides market. The regions covered in the veterinary parasiticides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary parasiticides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The veterinary parasiticides market consists of sales of macrocyclic lactones, benzimidazoles, imidazothiazoles, piperazines, and salicylanilides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.